CGE Healthcare

China Grand Enterprises Pharmaceutical & Healthcare is composed of Huadong Medicine Group, Grand Pharmaceutical Group, Grand Life Sciences Group, and Leiyunshang Pharmaceutical Group. As a comprehensive healthcare group with a wide range of therapeutic focus, a rich product portfolio, and leading scientific capabilities, we provide over 1,000 pharmaceutical and healthcare-related products, including drugs, medical devices, APIs, chemical intermediates, and science-based health products. We have built a global R&D and manufacturing network spanning Europe, North America, and Asia, with a focus on innovative medicines, radiopharmaceutical diagnosis and therapy, advanced formulations, mRNA therapeutics, and high-end medical devices. To date, we have established five R&D technology platforms and eight R&D centers across China, the United States, Australia, Germany, and Belgium. Centering on anti-tumor diagnosis and therapy, we have formed globally integrated radiopharmaceutical industrial chains with Boston and Chengdu as core R&D hubs, supported by production bases located in Boston, Frankfurt, Singapore, and Chengdu. In the field of comprehensive health aesthetics, our global R&D headquarters is located in Chester, United Kingdom, with specialized R&D centers in the Netherlands, France, Switzerland, Israel, and Boston (USA). We operate six global manufacturing sites for aesthetic health products across the Netherlands, France, the United States, Switzerland, Bulgaria, and Israel. Backed by a strong global commercial network, our marketing and sales coverage extends worldwide. Multiple products have obtained EU COS and U.S. FDA certifications, and are distributed to numerous countries and regions, gaining broad market recognition and trust.

CGE Healthcare adopts a “research-driven, patient-centered, and market-oriented” approach. Through internal R&D, industry partnerships, and global collaborations, we tackle health challenges and drive innovation across a wide range of healthcare solutions.